| Prev Close | 140.23 |
| Open | 140.01 |
| Day Low/High | 139.91 / 140.97 |
| 52 Wk Low/High | 120.11 / 148.99 |
| Volume | 6.37M |
| Avg Volume | 6.49M |
Johnson & Johnson (JNJ)
140.45
0.22
0.16
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.66B |
| Market Cap | 370.22B |
| EPS | 5.70 |
| P/E Ratio | 25.94 |
| Div & Yield | 3.80 (2.61%) |
Latest News
Band-Aids Cannot Help Johnson & Johnson in This Decline
Let's take a serious look at the charts and indicators.
Water Company Dividend Kings That Quench the Thirst for Income
Dividend stock investors should look to have at least some exposure to this sector.
Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.
Be Careful With Healthcare Stocks Here
Especially when healthcare CEOs discus political issues with analysts and reporters.
Johnson & Johnson and United Healthcare Face a Series of Obstacles
Recapping a big day of earnings for both names.
Fed's Evans Knows Nothing, China Q1 GDP, Trading Netflix: Market Recon
When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.
How to Trade Johnson & Johnson During Earnings Week
The biggest challenge is even if JNJ beats and raises guidance, the overhang of litigation could still prevent overzealous trading.
Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Jim Cramer: The Fed's Dramatic Sea Change and What It Means for Stocks Now
The best stocks to buy in this environment are the ones that have the greatest growth.
How to Play the Fed's Gift to the Markets (One Way Is With Netflix)
Wednesday was the first day that Netflix traded on above-average volume since Jan. 24.
The Rally in Johnson & Johnson Looks Like it has Run Its Course
Let's check out the charts.
Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult
Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.
Digging Down on the Dow 30
Just 13 of the 30 Dow components are in clear uptrends.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case
Let's look at the charts and indicators to round out the picture.
Jim Cramer: This Market Has a Terrible Case of Attention Deficit Disorder
I think this truly defines what has gone on with tech stocks since the latest reporting period began.
How Are My Ideas Working Out? January Trade Review (Part 1)
Eight of these 11 trade ideas are in the green, with a few big winners.
Jim Cramer: This Strong Dollar Is Biting Deeply Into Apple
Dollar strength is affecting the competitive advantage of U.S. companies around the globe, and it is a more insidious problem that most people recognize.
The New Small Biotechs Heating Up the Medical Cannabis Space
These companies are working to plant their flag in a new landscape.
Jim Cramer: What Are We to Make of Today's Market Decline?
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
How to Play Johnson & Johnson Now That Earnings Are Out
There's a lot of runway left to adjust guidance numbers moving forward.
My Greatest Concern About Procter & Gamble Heading Into Earnings
Volatility appears to be the most attractive play during the early portion of earnings season.
Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Johnson & Johnson: How the Stock Looks on the Charts After Earnings
Experienced traders could approach the long side carefully.
